Karen Mulder

Summary

Publications

  1. doi request reprint The role of bevacizumab in colorectal cancer: understanding its benefits and limitations
    Karen Mulder
    Cross Cancer Institute, Department of Medical Oncology, 11560 University Avenue, Edmonton, Alberta, Canada
    Expert Opin Biol Ther 11:405-13. 2011
  2. doi request reprint Renal dysfunction in a renal transplant patient treated concurrently with cyclosporine and imatinib
    Karen E Mulder
    Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
    Invest New Drugs 30:2400-2. 2012
  3. pmc Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future
    Karen Mulder
    Medical Oncology, Cross Cancer Institute, University of Alberta, Alberta, Canada
    Oncotarget 1:515-29. 2010
  4. pmc Targeting metastatic upper gastrointestinal adenocarcinomas
    Jennifer L Spratlin
    Jennifer L Spratlin, Quincy Chu, Sheryl Koski, Karen King, Karen Mulder, Cross Cancer Institute, University of Alberta, T6G 1Z2, Edmonton, Alberta, Canada
    World J Clin Oncol 2:135-49. 2011
  5. doi request reprint Impact of a dedicated cancer center surveillance program on guideline adherence for patients with stage II and III colorectal cancer
    Leah Standeven
    Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
    Clin Colorectal Cancer 12:103-12. 2013

Collaborators

  • Michael B Sawyer
  • Jennifer L Spratlin
  • Leah Standeven
  • George Zhu
  • Julie Price Hiller
  • Sunita Ghosh
  • Karen King
  • Sheryl Koski
  • Quincy Chu

Detail Information

Publications5

  1. doi request reprint The role of bevacizumab in colorectal cancer: understanding its benefits and limitations
    Karen Mulder
    Cross Cancer Institute, Department of Medical Oncology, 11560 University Avenue, Edmonton, Alberta, Canada
    Expert Opin Biol Ther 11:405-13. 2011
    ....
  2. doi request reprint Renal dysfunction in a renal transplant patient treated concurrently with cyclosporine and imatinib
    Karen E Mulder
    Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
    Invest New Drugs 30:2400-2. 2012
    ..1 ng/ml and 139 ng/ml). In our patient, imatinib initiation resulted in renal toxicity most likely due to its interaction with cyclosporine resulting in elevation of the whole blood cyclosporine concentration...
  3. pmc Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future
    Karen Mulder
    Medical Oncology, Cross Cancer Institute, University of Alberta, Alberta, Canada
    Oncotarget 1:515-29. 2010
    ..In this review, we will present the benefits, or lack thereof, of clinically tested antiangiogenic compounds in GI malignancies and explore some potential new therapeutic anti-angiogenesis options for these diseases...
  4. pmc Targeting metastatic upper gastrointestinal adenocarcinomas
    Jennifer L Spratlin
    Jennifer L Spratlin, Quincy Chu, Sheryl Koski, Karen King, Karen Mulder, Cross Cancer Institute, University of Alberta, T6G 1Z2, Edmonton, Alberta, Canada
    World J Clin Oncol 2:135-49. 2011
    ..Additionally, we will explore a few novel pathways that may prove effective in the treatment of upper GI malignancies in the near future...
  5. doi request reprint Impact of a dedicated cancer center surveillance program on guideline adherence for patients with stage II and III colorectal cancer
    Leah Standeven
    Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
    Clin Colorectal Cancer 12:103-12. 2013
    ..We found that a dedicated intensive surveillance program can impact adherence to guidelines for patients with colorectal cancer...